肝肿瘤的选择性内放射治疗:早期前景尚未兑现
选择性内放射治疗(SIRT)经肝动脉导管递送治疗性放射性药物或放射性颗粒,用于治疗原发性和继发性肝肿瘤。早期结果有前景,但3期随机对照试验对比全身化疗结果令人失望。近期将肿瘤辐射剂量提高至至少60Gy并联合更有效的全身治疗开始产生更好的临床结果,血管造影方法进步使其成为日间手术,Ho-166和Re-188等新核素拓宽了SIRT技术选择。
要点
- SIRT经肝动脉导管递送放射性药物或放射性颗粒,用于原发性和继发性肝肿瘤。
- 3期随机对照试验中SIRT对比全身化疗结果令人失望。
- 肿瘤剂量至少60Gy联合更有效全身治疗开始产生更好临床结果。
核心结论
- SIRT早期结果有前景,但3期随机对照试验对比全身化疗结果令人失望。
- 近期将肿瘤辐射剂量提高至至少60Gy并联合更有效的全身治疗开始产生更好的临床结果。
研究设计与样本
- 本文为综述,回顾SIRT过去30年的技术演变与临床应用。
主要发现
- SIRT通常经影像学放置的肝动脉内导管递送治疗性放射性药物或放射性颗粒。
- 多数肝肿瘤为单一动脉供血,而正常肝细胞由肝动脉和门静脉双重供血。
- 最初使用I-131标记罂粟籽油,但仅在少数中心使用。
- Y-90颗粒广泛可及后该技术更为普及。
- 血管造影方法进步使SIRT成为日间手术,Ho-166和Re-188等新核素拓宽了可能的SIRT技术范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Selective intra-arterial radiotherapy (SIRT) is a technique which has evolved over the past 30 years. In present this is primarily used to treat primary and secondary tumors in the liver. The technique normally depends on the delivery of a therapeutic radiopharmaceutical or radiolabeled particulate via a radiologically placed intra-arterial catheter in the hepatic artery. This is because most of these tumors have a single arterial blood supply but normal hepatocytes are supplied by both the hepatic artery and portal vein. Initially, this was done with I-131 labelled poppy seed oil but this technique was only used in a few centers. The technique became more popular when Y-90 particulates become widely available. Early results were promising but in phase 3 randomized controlled trials resulted in disappointing results compared to systemic chemotherapy. More recent work however, have shown that increasing the radiation dose to the tumor to at least 60Gy and combining with more effective systemic therapies are starting to produce better clinical results. There have also been advances in the angiographic methods used to make this into a day-case technique and the use of new radionuclides such as Ho-166 and Re-188 provides a wider range of possible SIRT techniques.
引用
- Buscombe J, Cwikla J, Quigley AM, et al. Selective Internal Radiotherapy in Liver Tumors: Early Promise Yet to be Fulfilled. Semin Nucl Med. 2024. PMID: 38627159. doi:10.1053/j.semnuclmed.2024.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。